NCT03869151

Brief Summary

To assess the prognostic role of pretreatment LMR in hepatocellular carcinoma(HCC).

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2019

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 7, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 11, 2019

Completed
25 days until next milestone

Study Start

First participant enrolled

April 5, 2019

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 5, 2020

Completed
26 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2020

Completed
Last Updated

April 2, 2019

Status Verified

March 1, 2019

Enrollment Period

11 months

First QC Date

March 7, 2019

Last Update Submit

March 31, 2019

Conditions

Hepatocellular Carcinoma

Outcome Measures

Primary Outcomes (1)

  • increased over all survival

    Elevated pretreatment lymphocyte monocyte ratio may be a favorable prognostic factor for clinical outcomes in patients with hepatocellular carcinoma.

    1 year

Interventions

CBCDIAGNOSTIC_TEST

lymphocyte and monocyte count

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Hepatocellular carcinoma patients

You may qualify if:

  • Patients with child A Hepatocellular carcinoma.

You may not qualify if:

  • Patients with child C Hepatocellular carcinoma.
  • Patients with heart failure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Officials

  • taha mahran, MD

    Assiut University

    STUDY CHAIR

  • ola abdelfatah, MD

    Assiut University

    STUDY CHAIR

  • aml ebraheem, MD

    Assiut University

    STUDY DIRECTOR

  • amany amin, master

    Assiut University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

amany Amin, master

CONTACT

+201093930042dr.ma777moud@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 7, 2019

First Posted

March 11, 2019

Study Start

April 5, 2019

Primary Completion

March 5, 2020

Study Completion

March 31, 2020

Last Updated

April 2, 2019

Record last verified: 2019-03